Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

Authors

  • Daniel C. Baumgart MD, PhD,

    Corresponding author
    1. Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt-University of Berlin, Germany
    • Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical Center – Virchow Hospital, Medical School of the Humboldt-University, D-13344 Berlin, Germany
    Search for more papers by this author
  • Ulrike Grittner PhD,

    1. Department of Biometry and Clinical Epidemiology, Humboldt-University of Berlin, Germany
    Search for more papers by this author
    • The first two authors contributed equally.

  • Andrea Steingräber RN,

    1. Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt-University of Berlin, Germany
    Search for more papers by this author
  • Marina Azzaro RN,

    1. Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt-University of Berlin, Germany
    Search for more papers by this author
  • Sandra Philipp MD

    1. Department of Dermatology, Charité Medical School, Humboldt-University of Berlin, Germany
    Search for more papers by this author

  • D.C.B. was a consultant for and received research support from Abbott Immunology for unrelated research projects. Abbott Immunology had no role in the design, data collection, data analysis, or interpretation of the results of this study.

Abstract

Background:

The monoclonal anti tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD).

Methods:

We evaluated the first 50 consecutive patients (female n = 30, median age 32½ years, interquartile range [IQR 27–46]) with CD (n = 46) and UC (n = 4) who received adalimumab (82% induction with 160/80 and 94% maintenance with 40 mg subcutaneously biweekly) at our center and were followed up for a median of 17 months [IQR 12–21]. The Kaplan–Meier method was used to estimate skin reaction free survival (SRFS) and Fisher's exact test to examine contingency between demographic variables and outcomes.

Results:

Sixty-two percent of all patients developed a dermatological reaction (eczema [n = 9], acne-like dermatitis [n = 9], psoriasis-like lesions [n = 6], localized erythema and swelling at injection site [n = 1], dermatitis sicca [n = 1], rosacea [n = 1], prurigo simplex [n = 1], tinea [n = 1], localized herpes simplex [n = 1], and candida [n = 1] infections) that resolved in 12% at follow-up. SRFS was 12 months [IQR 30–5]. Adalimumab was discontinued in 22% of all patients. Longer disease duration, a lower dose induction schedule, as well as concomitant use of steroids or immunosuppressants were more often associated with an unfavorable skin outcome. Skin outcomes differed significantly between patients who saw a dermatologist (P = 0.022) and/or had a dermatological intervention (P = 0.012).

Conclusions:

A broad spectrum of adverse cutaneous reactions occurs more frequently and later in adalimumab therapy for IBD compared with other indications. Consultation with a dermatologist is highly recommended. (Inflamm Bowel Dis 2011)

Ancillary